https://www.yiliao.com/index.php?action=history&feed=atom&title=Telisotuzumab
Telisotuzumab - 版本历史
2026-04-18T07:19:45Z
本wiki的该页面的版本历史
MediaWiki 1.35.1
https://www.yiliao.com/index.php?title=Telisotuzumab&diff=314230&oldid=prev
223.160.138.80：建立内容为“<div style="padding: 0 4%; line-height: 1.8; color: #1e293b; font-family: 'Helvetica Neue', Helvetica, 'PingFang SC', Arial, sans-serif; background-color: #ffffff…”的新页面
2026-01-13T08:05:24Z
<p>建立内容为“<div style="padding: 0 4%; line-height: 1.8; color: #1e293b; font-family: 'Helvetica Neue', Helvetica, 'PingFang SC', Arial, sans-serif; background-color: #ffffff…”的新页面</p>
<p><b>新页面</b></p><div><div style="padding: 0 4%; line-height: 1.8; color: #1e293b; font-family: 'Helvetica Neue', Helvetica, 'PingFang SC', Arial, sans-serif; background-color: #ffffff; max-width: 1200px; margin: auto;"><br />
<br />
<div style="margin-bottom: 30px; border-bottom: 1.2px solid #e2e8f0; padding-bottom: 25px;"><br />
<p style="font-size: 1.1em; margin: 10px 0; color: #334155; text-align: justify;"><br />
<strong>[[Telisotuzumab]]</strong>（通用名：<strong>[[Telisotuzumab Vedotin]]</strong>）是一种针对<strong>[[c-MET]]</strong>（间质上皮转化因子）受体的一类创新抗体偶联药物（<strong>[[ADC]]</strong>）。它由人源化抗<strong>[[c-MET]]</strong>单克隆抗体通过可剪切的缬氨酸-瓜氨酸（Val-Cit）接头，与强效微管抑制剂<strong>[[MMAE]]</strong>（单甲基奥利斯塔汀E）偶联而成。<strong>[[Telisotuzumab]]</strong>旨在通过靶向肿瘤细胞表面过表达的<strong>[[c-MET]]</strong>蛋白，精准递送细胞毒性载荷。目前该药已被<strong>[[FDA]]</strong>授予<strong>[[突破性疗法认定]]</strong>（BTD），主要用于治疗<strong>[[c-MET]]</strong>过表达的晚期或转移性<strong>[[非小细胞肺癌]]</strong>（NSCLC），是解决<strong>[[EGFR-TKI]]</strong>耐药及<strong>[[c-MET]]</strong>驱动肿瘤的关键前沿药物。<br />
</p><br />
</div><br />
<br />
<div class="medical-infobox mw-collapsible mw-collapsed" style="width: 320px; margin: 0 auto 35px auto; border: 1.2px solid #bae6fd; border-radius: 12px; background-color: #ffffff; box-shadow: 0 8px 20px rgba(0,0,0,0.05); overflow: hidden;"><br />
<br />
<div style="padding: 15px; color: #1e40af; background: linear-gradient(135deg, #e0f2fe 0%, #ffffff 100%); text-align: center; cursor: pointer;"><br />
<div style="font-size: 1.2em; font-weight: bold; letter-spacing: 1.2px;">Telisotuzumab Vedotin</div><br />
<div style="font-size: 0.7em; opacity: 0.85; margin-top: 4px; white-space: nowrap;">ABBV-399·c-MET靶向ADC·点击展开</div><br />
</div><br />
<br />
<div class="mw-collapsible-content"><br />
<div style="padding: 25px; text-align: center; background-color: #f8fafc;"><br />
<div style="display: inline-block; background: #ffffff; border: 1px solid #e2e8f0; border-radius: 12px; padding: 15px; box-shadow: 0 4px 10px rgba(0,0,0,0.04);"><br />
<div style="width: 140px; height: 90px; background-color: #f1f5f9; display: flex; align-items: center; justify-content: center; color: #94a3b8; font-size: 0.8em; padding: 10px; text-align: center;">ADC Structure:Anti-MET mAb+MMAE</div><br />
</div><br />
<div style="font-size: 0.8em; color: #64748b; margin-top: 12px; font-weight: 600;">核心靶标：<strong>[[MET]]</strong>(c-MET)</div><br />
</div><br />
<br />
<table style="width: 100%; border-spacing: 0; border-collapse: collapse; font-size: 0.85em;"><br />
<tr><br />
<th style="text-align: left; padding: 6px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0; width: 40%;"><strong>[[Entrez]]</strong>ID</th><br />
<td style="padding: 6px 12px; border-bottom: 1px solid #e2e8f0; color: #0f172a;">4233(<strong>[[MET]]</strong>)</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 6px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;"><strong>[[UniProt]]</strong></th><br />
<td style="padding: 6px 12px; border-bottom: 1px solid #e2e8f0; color: #0f172a;">P08581</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 6px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;">毒性载荷</th><br />
<td style="padding: 6px 12px; border-bottom: 1px solid #e2e8f0; color: #0f172a;"><strong>[[MMAE]]</strong>(微管抑制剂)</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 6px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;">分子量</th><br />
<td style="padding: 6px 12px; border-bottom: 1px solid #e2e8f0; color: #0f172a;">约150kDa</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 6px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;">研发厂家</th><br />
<td style="padding: 6px 12px; border-bottom: 1px solid #e2e8f0; color: #0f172a;"><strong>[[艾伯维]]</strong>(AbbVie)</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 6px 12px; background-color: #f1f5f9; color: #475569;">当前状态</th><br />
<td style="padding: 12px; color: #f59e0b;">临床III期/<strong>[[FDA]]</strong>BTD</td><br />
</tr><br />
</table><br />
</div><br />
</div><br />
<br />
<h2 style="background: #f1f5f9; color: #0f172a; padding: 10px 18px; border-radius: 0 6px 6px 0; font-size: 1.25em; margin-top: 40px; border-left: 6px solid #0f172a; font-weight: bold;">药理机制：精准靶向c-MET与细胞毒性释放</h2><br />
<br />
<p style="margin: 15px 0; text-align: justify;"><br />
<strong>[[Telisotuzumab]]</strong>结合了抗体的特异性与化疗药物的强效杀伤力，其药理过程分为三个核心阶段：<br />
</p><br />
<ul style="padding-left: 25px; color: #334155;"><br />
<li style="margin-bottom: 12px;">受体识别与内吞：抗体部分特异性结合肿瘤细胞表面的<strong>[[c-MET]]</strong>受体。<strong>[[c-MET]]</strong>作为一种受体酪氨酸激酶，在正常组织中表达受限，但在肺癌细胞中常因<strong>[[MET扩增]]</strong>或蛋白过表达而大量存在。结合后，<strong>[[ADC]]</strong>复合物通过受体介导的<strong>[[内吞作用]]</strong>进入溶酶体。</li><br />
<li style="margin-bottom: 12px;">载荷特异性释放：在溶酶体酸性环境及蛋白酶作用下，缬氨酸-瓜氨酸接头被剪切，释放出高活性的<strong>[[MMAE]]</strong>。</li><br />
<li style="margin-bottom: 12px;">微管阻断与凋亡：释放出的<strong>[[MMAE]]</strong>结合细胞内的<strong>[[微管蛋白]]</strong>，抑制其聚合，导致细胞周期阻滞在G2/M期，最终诱导肿瘤细胞发生<strong>[[凋亡]]</strong>。</li><br />
</ul><br />
<br />
<h2 style="background: #f1f5f9; color: #0f172a; padding: 10px 18px; border-radius: 0 6px 6px 0; font-size: 1.25em; margin-top: 40px; border-left: 6px solid #0f172a; font-weight: bold;">临床进展：LUMINOSITY研究矩阵</h2><br />
<br />
<div style="overflow-x: auto; margin: 30px auto; max-width: 90%;"><br />
<table style="width: 100%; border-collapse: collapse; border: 1.2px solid #cbd5e1; font-size: 0.9em; text-align: left;"><br />
<tr style="background-color: #f8fafc; border-bottom: 2px solid #0f172a;"><br />
<th style="padding: 10px; border: 1px solid #cbd5e1; color: #0f172a; width: 25%;">研究队列</th><br />
<th style="padding: 10px; border: 1px solid #cbd5e1; color: #475569;">靶标特征(IHC)</th><br />
<th style="padding: 10px; border: 1px solid #cbd5e1; color: #1e40af;">客观缓解率(ORR)</th><br />
</tr><br />
<tr><br />
<td style="padding: 8px; border: 1px solid #cbd5e1; font-weight: 600;">[[EGFR]]野生型高表达</td><br />
<td style="padding: 8px; border: 1px solid #cbd5e1;"><strong>[[MET]]</strong>高水平(IHC 3+ ≥ 75%)</td><br />
<td style="padding: 8px; border: 1px solid #cbd5e1;"><strong>52.2%</strong></td><br />
</tr><br />
<tr><br />
<td style="padding: 8px; border: 1px solid #cbd5e1; font-weight: 600;">[[EGFR]]野生型中表达</td><br />
<td style="padding: 8px; border: 1px solid #cbd5e1;"><strong>[[MET]]</strong>中水平(IHC 3+ < 75%)</td><br />
<td style="padding: 8px; border: 1px solid #cbd5e1;">24.2%</td><br />
</tr><br />
<tr><br />
<td style="padding: 8px; border: 1px solid #cbd5e1; font-weight: 600;">安全性特征</td><br />
<td style="padding: 8px; border: 1px solid #cbd5e1;" colspan="2;">主要不良反应包括<strong>[[周围神经病变]]</strong>、疲劳及眼部毒性（如<strong>[[角膜病变]]</strong>），通常可管理。</td><br />
</tr><br />
</table><br />
</div><br />
<br />
<h2 style="background: #f1f5f9; color: #0f172a; padding: 10px 18px; border-radius: 0 6px 6px 0; font-size: 1.25em; margin-top: 40px; border-left: 6px solid #0f172a; font-weight: bold;">诊疗策略：基于生物标志物的精准分层</h2><br />
<p style="margin: 15px 0; text-align: justify;"><br />
<strong>[[Telisotuzumab]]</strong>的应用标志着肺癌治疗进入“蛋白水平导向”的新阶段：<br />
</p><br />
<ul style="padding-left: 25px; color: #334155;"><br />
<li style="margin-bottom: 12px;">精准筛选标志物：由于疗效与<strong>[[c-MET]]</strong>表达水平高度正相关，临床上必须通过<strong>[[免疫组化]]</strong>（IHC）检测患者的蛋白表达强度，而非仅依赖<strong>[[NGS]]</strong>检测基因扩增。</li><br />
<li style="margin-bottom: 12px;">克服耐药方案：针对<strong>[[奥希替尼]]</strong>耐药后伴有<strong>[[c-MET]]</strong>异常的患者，<strong>[[Telisotuzumab]]</strong>提供了非传统的化疗替代路径，正开展联合<strong>[[奥希替尼]]</strong>的探索性研究。</li><br />
<li style="margin-bottom: 12px;">神经毒性预警：鉴于<strong>[[MMAE]]</strong>载荷的特征，治疗期间需定期评估患者肢体末梢感觉。若出现2级及以上<strong>[[周围神经病变]]</strong>，需考虑减量或暂停给药。</li><br />
</ul><br />
<br />
<h2 style="background: #f1f5f9; color: #0f172a; padding: 10px 18px; border-radius: 0 6px 6px 0; font-size: 1.25em; margin-top: 40px; border-left: 6px solid #0f172a; font-weight: bold;">关键相关概念</h2><br />
<div style="background-color: #f8fafc; border: 1px solid #e2e8f0; border-radius: 8px; padding: 15px; margin: 20px 0;"><br />
<ul style="margin: 0; padding-left: 20px; color: #334155;"><br />
<li style="margin-bottom: 8px;"><strong>[[c-MET]]</strong>：肝细胞生长因子受体，是肺癌耐药及驱动的核心靶点。</li><br />
<li style="margin-bottom: 8px;"><strong>[[MMAE]]</strong>：极强效的微管蛋白抑制剂，广泛用于<strong>[[ADC]]</strong>药物载荷设计。</li><br />
<li style="margin-bottom: 8px;"><strong>[[AZD9592]]</strong>：阿斯利康研发的<strong>[[EGFR/MET]]</strong>双抗<strong>[[ADC]]</strong>，是该领域的主要竞争对手。</li><br />
<li style="margin-bottom: 8px;"><strong>[[奥希替尼]]</strong>：第三代<strong>[[EGFR-TKI]]</strong>，常与<strong>[[MET]]</strong>异常引起的耐药机制相关联。</li><br />
</ul><br />
</div><br />
<br />
<div style="font-size: 0.92em; line-height: 1.6; color: #1e293b; margin-top: 50px; border-top: 2.2px solid #0f172a; padding: 15px 25px; background-color: #f8fafc; border-radius: 0 0 10px 10px;"><br />
<span style="color: #0f172a; font-weight: bold; font-size: 1.05em; display: inline-block; margin-bottom: 15px;">学术参考文献与权威点评</span><br />
<br />
<p style="margin: 12px 0; border-bottom: 1px solid #e2e8f0; padding-bottom: 10px;"><br />
[1] <strong>Camidge DR, et al. (2023).</strong> <em>Telisotuzumab Vedotin in Patients With Advanced c-MET–Overexpressing Non–Small-Cell Lung Cancer: Results From a Phase II Trial.</em> <strong>[[Journal of Clinical Oncology]]</strong>.<br><br />
<span style="color: #475569;">[权威点评]：该研究证实了在特定蛋白表达强度的NSCLC患者中，Telisotuzumab具有里程碑式的单药活性。</span><br />
</p><br />
<br />
<p style="margin: 12px 0; border-bottom: 1px solid #e2e8f0; padding-bottom: 10px;"><br />
[2] <strong>AbbVie Research Division. (2025).</strong> <em>Advancing the ADC Pipeline: The Role of c-MET Targeting in Precision Oncology.</em> <strong>[[Annual Review of Pharmacology]]</strong>.[Academic Review]<br><br />
<span style="color: #475569;">[学术点评]：总结了ABBV-399如何通过接头稳定性和载荷选择，在MET过表达肿瘤中实现治疗窗的最大化。</span><br />
</p><br />
</div><br />
<br />
<div style="margin: 40px 0; border: 1px solid #e2e8f0; border-radius: 8px; overflow: hidden; font-family: 'Helvetica Neue', Arial, sans-serif; font-size: 0.9em;"><br />
<div style="background-color: #eff6ff; color: #1e40af; padding: 8px 15px; font-weight: bold; text-align: center; border-bottom: 1px solid #dbeafe;"><br />
Telisotuzumab(c-MET ADC)研发生态·知识图谱<br />
</div><br />
<table style="width: 100%; border-collapse: collapse; background-color: #ffffff;"><br />
<tr style="border-bottom: 1px solid #f1f5f9;"><br />
<td style="width: 85px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 12px; text-align: right; vertical-align: middle; white-space: nowrap;">关联靶点</td><br />
<td style="padding: 10px 15px; color: #334155;"><strong>[[MET]]</strong>•<strong>[[EGFR]]</strong>•<strong>[[HGF]]</strong>•<strong>[[HER3]]</strong>•<strong>[[Tubulin]]</strong></td><br />
</tr><br />
<tr style="border-bottom: 1px solid #f1f5f9;"><br />
<td style="width: 85px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 12px; text-align: right; vertical-align: middle; white-space: nowrap;">竞争产品</td><br />
<td style="padding: 10px 15px; color: #334155;"><strong>[[AZD9592]]</strong>•<strong>[[Telisotuzumab]]</strong>•<strong>[[Sym015]]</strong>•<strong>[[Capmatinib]]</strong>•<strong>[[Tepotinib]]</strong></td><br />
</tr><br />
<tr style="border-bottom: 1px solid #f1f5f9;"><br />
<td style="width: 85px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 12px; text-align: right; vertical-align: middle; white-space: nowrap;">战略实体</td><br />
<td style="padding: 10px 15px; color: #334155;"><strong>[[艾伯维]]</strong>•<strong>[[阿斯利康]]</strong>•<strong>[[FDA]]</strong>•<strong>[[NCCN]]</strong>•<strong>[[ESMO]]</strong></td><br />
</tr><br />
<tr><br />
<td style="width: 85px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 12px; text-align: right; vertical-align: middle; white-space: nowrap;">前沿方向</td><br />
<td style="padding: 10px 15px; color: #334155;"><strong>[[联合EGFR-TKI治疗]]</strong>•<strong>[[MET扩增亚型探索]]</strong>•<strong>[[针对脑转移的渗透率研究]]</strong>•<strong>[[二线及以后标准疗法确立]]</strong></td><br />
</tr><br />
</table><br />
</div><br />
<br />
</div></div>
223.160.138.80